Laborie has struck a $239 million deal to buy Cogentix Medical. The takeover will give Laborie control of devices for the treatment of overactive bladder (OAB) and stress urinary incontinence (SUI).
Cogentix has built its business around a urology portfolio spearheaded by a neuromodulation device to treat overactive bladder and a soft-tissue bulking agent for managing stress urinary incontinence. Double-digit urology growth last year took the unit’s annual sales up toward the $50 million mark, pushing Cogentix’s overall revenues beyond $56 million.
The revenue figure is well short of the three-year goal Cogentix set when it was created through the 2015 merger of Uroplasty and Vision-Sciences. But equally it is up on the period shortly after the merger when a combination of debt and competition from the far-larger Medtronic threatened Cogentix’s prospects. A subsequent investment by Accelmed and conversion of the debt into equity enabled Cogentix to invest in its sales team and fight back.
Accelmed has been rewarded with a big return on the stock it picked up when Cogentix was at a low ebb. The payday follows Laborie’s identification of Cogentix’s Urgent PC Neuromodulation System and Macroplastique as a good fit for its urology business.
“The acquisition of Cogentix advances our strategy to invest in leading technologies that provide product and channel scale to Laborie’s existing urology strategic business unit diagnostic and therapeutic portfolio, particularly in the areas of OAB and SUI,” Laborie CEO Michael Frazzette said in a statement.
When the deal closes, Cogentix’s products will slot into a business unit that already sells ultrasound bladder scanners, pelvic floor diagnostics and other urology devices. Laborie is paying a 14% premium over Cogentix’s closing price the day before the deal was disclosed to acquire the device manufacturer.
By Nick Paul Taylor
Source: Fierce Biotech
While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape. Massive policy overhauls under President Trump’s second administration are likely to ripple well into the future, and that’s driving changes to the way drugmakers do business, experts say.
Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add 700 employees to its rolls, the Swiss drugmaker says it is making moves in its home country that will eliminate 550 jobs at one site and add 80 at another.
The Food for the Brain Foundation’s Cognitive Function Test is set to play a central role in the UK-based ‘READ OUT’ trial, which is investigating blood biomarkers to improve dementia diagnosis. The project, led by Professor Vanessa Raymont at the University of Oxford, forms part of the Blood Biomarker Challenge that aims to integrate blood tests into NHS dementia diagnostic pathways.
